Closed to Follow-up
IMPAACT P1101, a Phase I/II PK study of Raltegravir in infants and children with HIV and TB, has closed to follow-up.
Closed to Follow-up
IMPAACT 2007, a phase I study of the safety and PK of maraviroc in HIV-1-exposed infants, has closed to follow-up.
NEWS
Primary results from the IMPAACT P1078/TB APPRISE study have been published in the 3 October 2019 issue of The New England Journal of Medicine.
Our mission
Our mission is to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
This document highlights major steps in protocol implementation and gives a quick look at accrual for each study. It is updated monthly.
Proposals for new IMPAACT studies may be submitted by internal or external investigators in the form of a three-page study "capsule" any time.
Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.
